US · Healthcare · Drug Manufacturers - General
EPS came in at 1.21 against a street estimate of 1.10 — a beat of 10.0%.
Analysts rate Sanofi ADR a buy (5 buy, 6 hold, 0 sell out of 11) with an average price target of $53.61.
| Fund | Stake |
|---|---|
| Dodge & Cox | 1.17% |
| Morgan Stanley - Brokerage Accounts | 0.45% |
| Fisher Asset Management, LLC | 0.44% |
| Bank of America Corp | 0.33% |
| Amvescap Plc. | 0.28% |
| JPMorgan Chase & Co | 0.27% |
| Mondrian Investment Partners Ltd | 0.23% |
| Brandes Investment Partners & Co | 0.17% |
| Document | Date |
|---|---|
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Sanofi and Regeneron expanded their more than 20-year antibody collaboration to add four next-generation, long-acting immunology a | 2026-10-01 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Sanofi plans to transfer 20 mature medicines and three manufacturing sites worldwide to Cheplapharm. • In return, Sanofi will rec | 2026-09-17 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Sanofi announced on August 4, 2026 that the European Commission approved MenQuadfi for infants from six weeks of age. • MenQuadfi | 2026-08-06 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • First-half 2026 net sales were €22,106 million, up 11.1% versus the first half of 2025 and up 15.7% at constant exchange rates. • | 2026-07-30 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Q2 2026 net sales were €11,597 million, up 17.8% at constant exchange rates (CER) and 16.0% at actual exchange rates. • H1 2026 s | 2026-07-30 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Sanofi filed its annual Form 20-F for the fiscal year ended December 31, 2025. • The company has 1,219,427,096 ordinary shares ou | 2026-02-17 |
| Annual report FY2024 (20-F) | 2025-02-13 |
| Annual report FY2023 (20-F) | 2024-02-23 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $2.42 / share ex-date May 4, 2026 · pay Jun 3, 2026 | 2026-05-04 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sanofi ADR — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.